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Abstract
A novel assay procedure has been developed to allow simultaneous activity discrimination in crude tissue extracts of the
three known mammalian nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1) isozymes. These enzymes
catalyse the same key reaction for NAD biosynthesis in different cellular compartments. The present method has been
optimized for NMNAT isozymes derived from Mus musculus, a species often used as a model for NAD-biosynthesis-related
physiology and disorders, such as peripheral neuropathies. Suitable assay conditions were initially assessed by exploiting
the metal-ion dependence of each isozyme recombinantly expressed in bacteria, and further tested after mixing them
in vitro. The variable contributions of the three individual isozymes to total NAD synthesis in the complex mixture was
calculated by measuring reaction rates under three selected assay conditions, generating three linear simultaneous
equations that can be solved by a substitution matrix calculation. Final assay validation was achieved in a tissue extract by
comparing the activity and expression levels of individual isozymes, considering their distinctive catalytic efficiencies.
Furthermore, considering the key role played by NMNAT activity in preserving axon integrity and physiological function, this
assay procedure was applied to both liver and brain extracts from wild-type and Wallerian degeneration slow (WldS) mouse.
WldS is a spontaneous mutation causing overexpression of NMNAT1 as a fusion protein, which protects injured axons
through a gain-of-function. The results validate our method as a reliable determination of the contributions of the three
isozymes to cellular NAD synthesis in different organelles and tissues, and in mutant animals such as WldS.
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Introduction
The reaction catalysed by nicotinamide mononucleotide
adenylyltransferase (NMNAT, EC 2.7.7.1) is universal in living
cells and the sole known source of pyridine dinucleotides.
Eukaryotic NMNATs transfer adenylate from ATP to nicotin-
amide mononucleotide or nicotinic acid mononucleotide, gener-
ating NAD or deamido-NAD, respectively, and PPi (Fig. 1). The
reaction is easily reversible with an equilibrium constant close to
unity [1] but the forward reaction is thought to be predominate
in vivo, as NAD homeostasis fails without NMNAT [2,3]. The
reverse reaction is most likely limited by the physiological absence
of PPi. In mammals, where the nicotinamide salvage pathway
generates most NAD, the metabolic flux is mainly controlled by
the preceding enzyme in the salvage pathway, nicotinamide
phosphoribosyltransferase [4], which can be inhibited by FK866
[5,6].
This highly conserved enzyme [7–10] has three isoforms in
mammals arising from multiple genes and showing distinctive
oligomerization properties, subcellular localization, and tissue
distribution [11–14]. NMNAT1, NMNAT2 and NMNAT3 are
predominantly localized in nuclei, Golgi membranes and mito-
chondria respectively. Human nuclear NMNAT1 is a homo-
hexamer of 32 kDa subunits [15] and is the most widely-expressed
isozyme and often the most abundant. The Golgi isozyme,
NMNAT2, remains structurally undefined but was recently
modelled in silico [16]. It is considered a 34 kDa monomer, most
abundant in neuronal tissues [17]. NMNAT2 appears unstable
and prone to oxidative denaturation due to its high cysteine
content, two of which form an isoform-distinctive doublet which is
palmitoylated to anchor NMNAT2 at the cytoplasmic surface of
Golgi membranes [18]. Human mitochondrial NMNAT3 is
a homo-tetramer of 28 kDa subunits [19], whose expression
pattern show little overlap with NMNAT2, and which is less
abundant than NMNAT1 [13,14,19]. One exception is human
erythrocytes, which have a remarkably high level of NMNAT3
relative to NMNAT1 [20].
Each mammalian NMNAT isozyme has a characteristic di-
valent cation dependence, affinity, and specificity [9,10]. They also
show differential use of alternative substrates as ITP and GTP, or
other purine nucleotide substrate analogs such as cancer
chemotherapeutic tiazofurin monophosphate [13,21]. Although
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the physiological relevance of these reactions remains unclear, the
selective substrate specificity and metal ion dependence should
allow the individual activities of the three human NMNATs to be
determined in complex cell or tissue extracts [13]. This is an
attractive tool to assess their relative contributions to NAD
synthesis in different cell types, organelles, and responses to
environmental stimuli, including any post-translational regulation.
The occurrence in mammalian cells of multiple, compartmen-
talized NMNAT isozymes strongly suggests that NAD biosynthesis
is differentially regulated in different subcellular compartments
[22], and the unequal distribution among mammalian tissues
[13,14] suggests tissue-specific functions, whose physiological and
pathological implications require further study. Subcellular
distribution is controlled by isoform-specific targeting and in-
teraction domains (ISTIDs) [18], encoded by unique exons, which
are absent in NMNATs from lower organisms and are dispensable
for catalytic activity. Interestingly, the ISTIDs include post-
translational modification sites, such as palmitoylation [23] or
phosphorylation [24], likely to regulate compartmentalization of
intracellular NAD pools. The roles of individual mammalian
NMNATs, other NAD biosynthetic enzymes and their metabolic
intermediates [22], are widely studied for example in DNA
protection, regulation of gene expression, cell death, lifespan, and
glucose metabolism [11,12,25,26]. Although an isozyme discrim-
ination method is available for the human enzymes [13], many of
these studies use mouse tissue and the human assay cannot be
directly transferred to other species where enzyme properties
differ.
One important example is the role of NMNAT in axon survival
and neuroprotection [12,27–30]. The progressive breakdown of
the distal segment of a severed axon, termed ‘‘Wallerian de-
generation’’, is a widespread, non-apoptotic death programme
shared with some axonopathies [31]. A spontaneous mutation in
mice, the Wallerian degeneration slow (WldS) mutation [32],
mutates NMNAT1, partly relocating it into axons. Understanding
the neurodegenerative mechanism has identified molecular steps
for pharmacological targeting [33], (Conforti et al., unpublished).
WldS expression markedly delays the axonal degeneration after
mechanical or chemical injuries, and also ameliorates several acute
or chronic neuropathies morphologically converging into pro-
gressive axon degeneration [28,34]. It has been proposed that
WldS compensates for loss of the major endogenous axonal
isozyme, NMNAT2, a labile protein that is essential for axon
survival [29,35,36]. Thus, WldS represents an extra NMNAT
isoform aberrantly present within the axoplasm of the mutant
strain, allowing protection through a gain-of-function whose
details are beginning to emerge (Conforti et al., unpublished).
An important limitation for research on this and other significant
topics relating to NMNAT has been the lack of methods to
distinguish the effects of individual isozyme activities, especially in
the absence of highly selective inhibitors. Most conclusions have
been inferred from RNA and protein quantification experiments,
but these are intrinsically unable to evaluate post-translational
regulation and often limited by the low quality of currently
available antibodies. Thus, a discrimination assay for mouse
isozymes would fill an important gap.
To allow direct estimates of the three endogenous NMNAT
isozyme activities in mouse tissues, as well as of the NAD-
biosynthetic machinery where WldS acts, a novel assay has been
developed and validated for simultaneous activity determination of
all known NMNAT isozymes. Its application to both brain and
liver extracts from WldS mice illustrates the potential for studying
isoform-specific biochemistry in mouse tissues, thus facilitating
future studies of how NMNAT isozymes respond individually to
disease, injury or ageing.
Methods
Ethics Statement
Procedures using live animals were authorised under Project
Licence 80/2254 that was approved both by the Babraham
Research Campus Animal Welfare, Experimentation and Ethics
Committee (AWEEC) and the UK Home Office. Animals were
humanely killed using approved (Schedule 1) methods.
Materials
Ni-NTA Superflow and TALONH metal affinity resins were
purchased from Qiagen and Clonetech, respectively. PD-10
SephadexTM columns were from GE Healthcare. E. coli strains
TOP10F’ and BL21(D3), SuperScriptTM II Reverse Transcriptase,
and PlatinumH SYBRH Green qPCR SuperMix UDG were from
Invitrogen. Protein Assay kit and Taq-polymerase iProofTH High-
Fidelity were from Bio-Rad. The pET28 expression vectors were
from Novagen. Other chemicals were from Sigma.
Mouse Genotypes and Tissue Extract Preparation
Livers and brains from wild-type (C57BL/6) and mutant WldS
mouse (C57BL/WldS) were obtained from a breeding colony
purchased from Harlan Laboratories (UK). Collected tissues were
immediately snap-frozen in liquid nitrogen and stored at 280uC
until the time of processing. Frozen mouse tissues were dipped into
liquid nitrogen and ground by mortar and pestle to a fine powder.
Thereafter, weighed tissue aliquots were extracted with perchloric
acid for HPLC determination of endogenous NAD levels [37],
using cAMP as an internal standard for recovery calculation.
Alternatively, for activity assays, they were resuspended in 10 vol
of 50 mM HEPES/KOH buffer, pH 7.5, 20 mM NaF, freshly
supplemented with 1 mM dithiothreitol (DTT), 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 0.02 mg/mL leupeptine,
antipain, chymostatin, pepstatin, and aprotinin. After gentle
thawing on ice, each homogenate was sonicated 3 times at 50
watts (30 sec each with 0.5-sec impulse) with 1-min intervals on
ice, and treated with Chelex-100 resin to remove interfering
endogenous metal ions. In this step, pre-swollen Chelex-100 resin,
washed twice with ice-cold distilled water just before the use, was
gently mixed at 1: 3 vol ratio and quickly removed by mild
centrifugation. Each metal-free supernatant was assayed to
determine protein concentration (Bio-Rad Protein Assay kit) and
immediately used for the discrimination assay (see below).
Cloning and Bacterial Overexpression
Full-length open reading frames encoding Mus musculus
NMNAT (mNMNAT) isoforms 1 (855 bp, GenBank
AY679721), 2 (921 bp, GenBanK BC089007), 3 (756 bp,
GenBanK BC005737), and WldS (1119 bp, GenBanK
AF260924), were amplified by standard high-fidelity PCR from
commercial plasmids. The primers used, carrying restriction
Figure 1. Overall NMNAT-catalyzed reaction. The mammalian
NMNAT enzymes belonging to EC 2.7.7.1 are involved in both amidated
and deamidated NAD biosynthesis pathways. NMN, nicotinamide
mononucleotide; NaMN, nicotinic acid mononucleotide; NaAD+, nico-
tinic acid adenine dinucleotide or deamido-NAD.
doi:10.1371/journal.pone.0053271.g001
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overhangs for directional cloning into the polylinker region of
pET28 vectors, are listed in supplemental Table S1. Directional
cloning was performed at NdeI/EcoRI of pET28c for mNMNAT1,
at NdeI/HindIII of pET28c for both mNMNAT2 and
mNMNAT3, and at NheI/XhoI of pET28b for WldS. Owing to
this cloning strategy, the recombinant proteins were all fused to N-
terminal His-Tag tails, i.e. MGSSHHHHHHSSGLVPRGSH for
the three mNMNATs, and
MGSSHHHHHHSSGLVPRGSHMAS for WldS. The resulting
plasmid constructs were replicated into E. coli TOP10F’, verified
by sequencing for their exact match with database deposited
sequences, and individually transformed into E. coli BL21(D3) for
protein expression. After transformation, single colonies from
kanamycin-selective plates were inoculated in 10 mL Luria-
Bertani medium supplemented with 50 mg/L kanamycin, and
grown at 37uC overnight under rotary shacking (200 rpm). About
5 mL of each pre-culture was inoculated in 250 mL fresh medium
without antibiotic, and grown as before but at the temperature of
28uC to prevent or minimize inclusion bodies formation. At
middle exponential phase (OD600 ,0.8, usually 3–4 h incuba-
tion), 1 mM isopropylthio-b-galactoside was added to each culture
and the induction was prolonged for additional 3 h at 28uC. Cells
were finally collected by mild centrifugation, washed twice with
PBS, and stored at 280uC.
Purification of Recombinant His-tagged Proteins
All purification steps were performed at 4uC. Harvested
bacterial cells expressing either mNMNAT1, or mNMNAT2, or
mNMNAT3, or WldS recombinant species, were lysed by
French Press at 18,000 psi after resuspension in 10–15 mL lysis
buffer composed by 50 mM Na-phosphate, pH 7.0, 300 mM
NaCl, 5 mM 3-(3-cholamidopropyl)dimethylammonium-2-hy-
droxy-1-propanesulfonate (CHAPSO) (for mNMNAT1 and
mNMNAT2), or 50 mM HEPES/KOH, pH 7.5, 500 mM
NaCl, 5 mM CHAPSO (for mNMNAT3 and WldS), in either
case freshly supplemented with 1 mM PMSF, 1 mM tris(2-
carboxyethyl)phosphine (TCEP), and 0.05 mL/g cell pellet of
protease inhibitor cocktail (Sigma #P8465). After brief in-
cubation in the presence of lysozyme (1 mg/mL) and DNAse
(10 mg/mL), the protein suspensions were clarified by centrifu-
gation at 20,0006g for 30 min. Thereafter, the His-tagged
mNMNAT3 and WldS species were purified by Ni-NTA affinity
chromatography, carried out onto pre-packed columns (0.5–
1 mL resin) equilibrated with 50 mM HEPES/KOH, pH 7.5,
500 mM NaCl, 1 mM TCEP, 1 mM PMSF. The washing and
elution steps were carried out using 20 mM and 200 mM
imidazole, respectively. Instead, the His-tagged mNMNAT1 and
mNMNAT2 species were purified by TALON affinity chroma-
tography, performed in 50 mM Na-phosphate buffer, pH 7.0,
300 mM NaCl, 1 mM TCEP, 1 mM PMSF. In this case, the
washing and elution steps were carried out using 20 mM and
150 mM imidazole, respectively. Collected fractions from each
chromatography were analysed by SDS-PAGE and assayed for
their total NMNAT activity (see below). Active and homoge-
neous fractions were pooled and quickly desalted on PD-10
columns against 50 mM HEPES/KOH buffer, pH 7.5, 20%
glycerol, 1 mM TCEP. Enzyme stability in solution was checked
after storage in aliquots at either 4uC or 220uC. Before their
use in discrimination assays, thawed samples were treated with
Chelex-100 resin as above described (see Tissue extract preparation).
NMNAT Activity Assays
Activity rates were measured by a C18-HPLC method [13,37],
based on measurement of the product formed by the NMNAT-
catalyzed reaction, i.e. NAD or its analogs (respectively, nicotin-
amide hypoxanthine dinucleotide from ITP and nicotinamide
guanine dinucleotide from GTP). Rates were calculated as tangent
lines in the linear region of plots of product accumulation versus
time. Kinetic parameters were measured as described [13] under
15% maximum consumption of both substrates concentration.
One unit (U) of NMNAT activity refers to the enzyme amount
catalysing 1 mmol/min product formation at 37uC.
The assays discriminating for individual isozyme activity
(discrimination assays) are based on isozyme-selective metal ion
dependence. The reference assay mixture (0.4 mL final volume)
contained 30 mM HEPES/KOH, pH 7.5, 0.6 mg/mL BSA,
25 mMMgCl2, 20 mM NaF, 1 mM DDT, 1 mM both NMN and
ATP, and either ,1 mg/mL protein tissue extract or 0.15–
2.5 mg/mL each pure recombinant isozyme. The above assay,
referred as ‘‘A’’, was used to measure total NMNAT activity, i.e.
the ‘‘reference’’ activity value for all different mNMNAT isoforms.
For isozyme discrimination, the additional mixtures ‘‘B’’, ‘‘C’’, and
‘‘D’’ were set replacing 25 mM MgCl2 with either 50 mM MgCl2
(B) or 1.5 mM ZnCl2 (C) or 4 mM CoCl2 (D). The assays under
condition ‘‘D’’ were carried out in the absence of DTT. Suitable
parameters for subsequent calculation were obtained by parallel
assaying of each recombinant isozyme under the four conditions
above. Then, reaction rates obtained from ‘‘B’’, ‘‘C’’, and ‘‘D’’
were divided each by the reference activity value obtained from
‘‘A’’. The resulting reaction rate ratios, i.e. the coefficients b1, b2,
b3; c1, c2, c3; d1, d2, d3, were substituted in the following system
of three linear equations:
Tissue NMNAT activity (condition assay
‘‘B’’) = (b1?X)+(b2?Y)+(b3?Z).
Tissue NMNAT activity (condition assay
‘‘C’’) = (c1?X)+(c2?Y)+(c3?Z).
Tissue NMNAT activity (condition assay
‘‘D’’) = (d1?X)+(d2?Y)+(d3?Z).
where X, Y, and Z represent the true enzymatic activities of
mNMNAT1, mNMNAT2, and mNMNAT3, respectively, in the
complex mixture. Solution of the matrix based on the Cramer’s
rule [38] yields the actual activity values X, Y, and Z as if they
were measured under reference condition ‘‘A’’. Matrix calculation
was carried out by Microsoft Excel and, specifically, by using the
functions MDETERM(array), MINVERSE(array) and MMUL-
T(array-1,array2), were ‘‘array’’ is the matrix of coefficients b1, b2,
b3; c1, c2, c3; d1, d2, d3; ‘‘array-1‘‘ is the transposed matrix of
‘‘array’’ obtained by the function MINVERSE(array), and
‘‘array2’’ is the vector obtained from tissue NMNAT activity
values under conditions ‘‘B’’, ‘‘C’’, and ‘‘D’’. The whole procedure
including a numerical example of the matrix substitution
calculation is detailed in Supporting Information files: Methods
S1, Table S2, and Methods S2.
Evaluation of mRNA Expression
Total RNA was extracted from frozen tissue samples by using
TriSure (Bioline) according to the manufacturer’s instructions.
First strand cDNA synthesis was performed using SuperScriptTM
II Reverse Transcriptase in the presence of 1 mg total RNA and
oligo(d)T primer. Quantitative real time PCR was performed
using PlatinumH SYBRH Green qPCR SuperMix UDG and the
primer pairs described in supplemental Table S1. The PCR
efficiency for each set of primers was previously established by
analysing serial dilutions of cDNA. All measurements were made
at least in duplicate and the relative expression levels of the three
mNMNATs were each normalized to the housekeeping gene b-
actin [39].
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Results
Comparative Kinetic, Catalytic Studies, and Selection of
Suitable Discrimination Assay Conditions
Similar to the previously reported human method [13], our
study of mNMNATs began using recombinant His-tagged
enzymes obtained after bacterial overproduction. Indeed, se-
quence identity between mouse and human NMNAT counter-
parts is high, i.e. ,80% for isoforms 1 and 3, and as high as 99%
for isoform 2, with only four substitutions out of 307 total residues
(not shown). After bacterial expression and one-step affinity
chromatography, the different purifications yielded similar results
and recovery values. Typically starting from 250 mL induced
bacterial cultures, 50–80 mg protein and 0.1–0.4 U/mg total
NMNAT activity were obtained in the soluble crude bacterial
extract, while 0.5–2 mg protein with ,80% activity yield were
recovered in the purified enzyme preparations. Under the
reference assay condition ‘‘A’’ (see Methods), the average specific
activity value for both mNMNAT1 and WldS final preparations
was ,30 U/mg, while ,5 U/mg and ,2.5 U/mg were ob-
served, respectively, for mNMNAT2 and mNMNAT3. Each final
preparation also showed a protein band of the expected molecular
mass after SDS-PAGE (Fig. 2A). Their stability in solution was
later assessed after storage at 4uC and 220uC in an appropriate
buffer at pH 7.5 containing both glycerol and TCEP as a reducing
agent. As shown in Figure 2B, only mNMNAT2 at 4uC was
rapidly inactivated, while similar stability at both temperatures was
observed in all other cases, with activity losses ranging from 27%
to 66% after six month storage. The comparable stability at –20uC
of all our preparations (Fig. 2B, bottom) indicated this condition is
optimal for long term storage of these expressed isozymes.
Further kinetic and catalytic characterization was conducted to
identify feasible conditions to discriminate the activity of individual
mouse isozymes in complex mixtures, in comparison with those
reported for human NMNATs [13]. Inclusion of the WldS
chimera was of potential relevance for the study of its individual
contribution to neuroprotection.
Similar to human NMNATs [13], the N-terminal His-Tag did
not affect the activity of the recombinant mouse enzymes. Their
catalytic parameters (Km, kcat, and catalytic efficiency kcat/Km) for
both NMN and ATP substrates were calculated from nonlinear
fitting on primary plots. As summarized in Table 1, mNMNAT1,
mNMNAT2, and mNMNAT3 showed substrate affinities in the
micromolar range and kcat values comparable to the corresponding
human isozymes. The catalytic efficiencies were also similar, with
the order mNMNAT1. mNMNAT2. mNMNAT3. The kinetic
behaviour of the WldS chimera was remarkably superimposable to
that of mNMNAT1, indicating that the N-terminal sequence of
WldS mutation (Ube4b fragment [40,41]) does not interfere with
the enzyme catalysis.
The activity discrimination of human NMNATs was based on
parallel determination under assay conditions ensuring only one
isozyme form is active at a time, e.g. by using high millimolar Zn2+
to select for isoform 1, low millimolar Mg2+ for isoform 2, and ITP
for isoform 3 [13]. The behaviour of mouse recombinant isozymes
under these conditions is summarized in Figure 3. In marked
contrast to human NMNAT1, mNMNAT1 and WldS were able to
use both ITP and GTP, supporting reaction rate ratios of 0.12 and
0.14, respectively, relative to the reference activity in the presence
Figure 2. Bacterial overexpression and stability of recombinant isozyme preparations. Panel A) SDS-PAGE analysis of affinity purified His-
tagged recombinant proteins. Gel lanes were loaded with standard protein markers of indicated mass values and 3–4 mg each of WldS (1), mNMNAT1
(2), mNMNAT2 (3), or mNMNAT3 (4) final enzyme preparation. ProtParam predicted masses of recombinant species are 44001 (1), 34518 (2), 36668 (3),
and 29866 (4) daltons. Panel B) Stability of each preparation at 4uC and 220uC in a buffer solution composed by 50 mM HEPES/KOH, pH 7.5, 20%
glycerol, and 1 mM TCEP.
doi:10.1371/journal.pone.0053271.g002
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of ATP (Fig. 3A). Conversely, closely resembling their human
counterparts, mNMNAT2 activity was barely detectable using
both alternative substrates, while mNMNAT3 showed a clear
preference for ITP with respect to GTP. Furthermore, in the
presence of various concentrations of the chloride salts of both
Mg2+ and Zn2+ (Fig. 3B and C), the resulting metal-dependence of
mNMNATs was largely similar to the corresponding human
isozymes [13], with the exception of mNMNAT1 and WldS,
whose Mg2+-dependence was superimposable with mNMNAT2
(Fig. 3B). These results show that the structurally-related
mNMNAT1 and WldS enzymes are catalytically indistinguishable
in all conditions tested. In addition, they clearly evidence
remarkable catalytic differences between mice and humans
regarding the sole isoform 1 that significantly appears more
flexible in mice in the acceptance of ITP and Mg2+. These
unexpected findings prevent utilization of our previous human
protocol for mouse and prompted us to develop an alternative.
In subsequent experiments, we repeatedly observed more than
one mNMNAT active at a time under a wide range of assay
conditions tested, including variation of pH, ionic strength,
temperature, and use of alternative substrates or metal cofactors
other than those reported in Figure 3 (not shown). This difficulty in
identifying conditions where only one isozyme was active,
prompted us instead to develop a method to calculate the
contribution of each isozyme using measurements made under
three different conditions. Using different metal ion species and
concentrations, we chose conditions that select for or against the
activities of each isoform, even though other isoforms remained
partially active (Fig. 3). This allowed us to generate three
simultaneous equations whose unknowns are the activities of the
three isozymes (see below). Two of the selected conditions, 50 mM
Mg2+ (Fig. 3B, condition ‘‘B’’) and 1.5 mM Zn2+ (Fig. 3C,
condition ‘‘C’’), are similar to those adopted in the previous human
discrimination assay [13]. The third condition, 4 mM Co2+
(Fig. 3D, condition ‘‘D’’) was selected because it supports a very
high activity for isozyme 3 and, to a lesser extent, for isozyme 1.
Furthermore, when Co2+ was used as cofactor, DTT was omitted
because it interfered with the activity of all three mNMNATs
leading to reaction rate reduction (not shown). In these assays,
metal-free enzyme preparations obtained by Chelex treatment
were used (see Methods), all displaying a maximum of 5% residual
activity in the absence of metals (not shown).
Calculation of Isozyme Activities in Mixtures
As the number of independent assay conditions is equal to
the number of isozymes, the three simultaneous equations can
be solved by Cramer’s rule [38]. To our knowledge, this
approach has not previously been used to determine individual
activities of multiple isozymes in unknown mixtures. In brief,
NMNAT activity under condition ‘‘A’’ (25 mM MgCl2) provides
a fixed reference point, and the reaction rate ratio relative to
this value is obtained for each mouse isozyme using pure
recombinant proteins under conditions ‘‘B’’, ‘‘C’’, and ‘‘D’’.
This indicates the nine coefficients reflecting the activity ratio
exerted at each condition by each isozyme (see Methods). In
parallel, the tissue NMNAT activity values under the same
three discrimination conditions are measured. These latter
values equal the sum of three distinct contributions, one by
each isozyme, referred as the isozyme activity sought, multiplied
by its coefficient (the reaction rate ratio). In this way, once all
nine coefficients and the three tissue NMNAT activities are
known, the three linear equations described in Methods can be
generated, and a substitution matrix calculation based on
Cramer’s rule can be easily applied to determine the three
isozyme activities, e.g. via a pre-formatted MS Excel spreadsheet
(see Methods S2). In Excel, the coefficients are arranged as
a matrix to calculate its own inverse and the corresponding
determinant; the tissue NMNAT activity values are then
arranged as a vector to be multiplied by the inverse matrix
above, thus yielding the three unknowns (X, Y, and Z). The
system has a unique solution only if the matrix determinant is
not zero. The three resulting values X, Y, and Z, represent the
individual isozyme contributions to total NAD formation in the
original native mixture under the ‘‘reference’’ condition ‘‘A’’,
that is used to assay total NMNAT activity in extracts from
normal and pathological tissues.
Analytical Validation
Validation of the proposed method was first carried out in vitro
as previously done for human isozymes [13], using mixtures
reconstituted from the three pure recombinant isozymes. Firstly,
similar activities of each isozyme were mixed, as measured under
condition ‘‘A’’ (reference condition, Table 2) and these known
values compared to individual values from the matrix calculation
(X, Y, and Z). The same reagent stocks were used for all assays to
minimize experimental variability. The fit ranged from 213% to
+7% suggesting this method provides reasonably accurate
estimates of the contribution of each isozyme (Table 2).
We then simulated biological variability by mixing unequal
isozyme amounts ranging from a minimum of 0.54 mU up to
a maximum of 2.40 mU as measured under reference condition
‘‘A’’ (Table 3). The results of four such independent experiments
Table 1. Kinetic parameters of mouse and human recombinant NMNAT isozymes.
ATP NMN
Km (mM) kcat (s21) kcat/Km (s21M21) Km (mM) kcat (s21) kcat/Km (s21M21)
WldS (a) 29.661.8 25.560.4 8.66105 32.261.2 25.860.4 8.06105
mNMNAT1 (a) 33.565.1 15.060.7 4.56105 25.265.6 15.561.3 6.16105
mNMNAT2 (a) 82.0615.1 2.3360.2 0.36105 38.5613.5 2.8760.5 0.76105
mNMNAT3 (a) 39.065.9 0.7460.04 0.26105 117.664.6 0.7560.02 0.16105
human NMNAT1 (b) 58.564.2 53.961.4 9.26105 22.362.6 53.863.4 24.16105
human NMNAT2 (b) 88.9618.3 8.860.4 1.06105 21.362.7 8.860.3 4.16105
human NMNAT3 (b) 42.165.8 2.560.3 0.66105 66.268.5 2.560.2 0.46105
(a) Data calculated in this work by using substrate concentrations in the range 25–175 mM for ATP and 5–100 mM for NMN; (b) data from ref [13].
doi:10.1371/journal.pone.0053271.t001
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are shown in Table 3: the various isozyme amounts mixed yielded
individual matrix-calculated values with percent errors ranging
from 28% to +15%. This indicated sufficient statistical accuracy,
regardless to the different proportions of isozymes mixed.
Further validation of the proposed assay was done directly on
a mouse tissue extract and compared to mRNA expression
following parallel protein and RNA extraction (Fig. 4). Wild-type
mouse brains were sagittally divided in the two cerebral hemi-
spheres, to be used for either activity discrimination assays or
quantitative RT-real time PCR. Specific activities of the three
isozymes were obtained as described by assaying tissue extracts
and pure recombinant mNMNATs in parallel, and relative
Figure 3. Use of alternative 59-triphosphate purine substrates and metal ion dependence of recombinant isozymes. All values are
averages (+/2 SD) from triplicate HPLC analyses and referred as reaction rate ratios relative to the reference activity (condition ‘‘A’’, see Methods).
Panel A) Individual isozymes were assayed in the presence of 1 mM ITP or GTP substrates, either replacing 1 mM ATP in the standard assay. Panels B,
C, and D) Individual isozymes were assayed at several concentrations of chloride salts of indicated metal ions, each replacing 25 mM MgCl2 in the
standard assay. The assays with CoCl2 were also performed in the absence of DTT. mNMNAT1 and Wld
S data are combined because these were
indistinguishable in all conditions tested. Boxed data points refer to the metal ion concentrations selected for discrimination in the present work, i.e.,
50 mM MgCl2 (B), 1.5 mM ZnCl2 (C), and 4 mM CoCl2 (D).
doi:10.1371/journal.pone.0053271.g003
Table 2. In vitro discrimination of mNMNAT activities (mU).
Reference condition Discrimination conditions
A B C D Matrix-calculated Error %
mNMNAT1 1.28 0.72 0.50 0.84 1.12 212%
mNMNAT2 1.85 0.02 0.63 0.14 1.98 +7%
mNMNAT3 1.64 0.19 0.05 3.21 1.42 213%
MIXED (4.77)b 0.81 1.15 3.62 (4.51)b 25%
Table shows data from a typical discrimination experiment where the three recombinant mouse isozymes have been assayed both separately and after mixing in
a reconstituted sample. The four assay conditions A, B, C, and D are described both in the text and in Methods. On the right, respectively, the activity values resulting
after matrix calculation and the percent errors with respect to the measured values under reference condition ‘‘A’’. (b) values in brackets are the sum of individual
isozyme activities.
doi:10.1371/journal.pone.0053271.t002
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expression levels normalized to b-actin. In these experiments,
either right or left hemispheres were taken randomly, to be used
for parallel protein and RNA extraction.
The sum of the three individual isozyme activities obtained from
matrix calculation was in good agreement with the experimental
value of 0.09260.009 mU/mg for total NMNAT activity
measured under reference condition ‘‘A’’ (25 mM MgCl2). In-
terestingly, total activity was almost entirely accounted for by
mNMNAT1 and mNMNAT2 alone (Fig. 4A). The differences
between activity and expression profiles are consistent with the
differential kinetic properties and protein stabilities of the in-
dividual isozymes. For example, mNMNAT1 has a turnover
number ,6 and ,20 times higher than mNMNAT2 and
mNMNAT3 respectively (see kcat values in Table 1), and
mNMNAT2 is known to be a much less stable protein than either
mNMNAT1 or mNMNAT3 [36] so its steady state protein level is
likely to be lower than suggested by mRNA. Post-translational
modification is another potential source of difference between
activity and mRNA profiles.
Discrimination Assay on Wild-type and WldS Mutant
Mouse Tissues
Application of the discrimination assay to wild-type brain and
liver tissues revealed clearly distinct isozyme activity patterns in the
corresponding extracts. mNMNAT1 (45%) and mNMNAT2
(50%) provided most activity in brain, while in liver mNMNAT1
(67%) and mNMNAT3 (30%) were most active (Fig. 5). In each
case, the third isozyme activity, mNMNAT3 in brain and
mNMNAT2 in liver, was barely detectable. Thus, these two
tissues show widely differing and almost mutually exclusive
patterns of NMNAT2 and NMNAT3 activity in keeping with
overall predictions from reported expression data [12–14].
Parallel activity discrimination analyses were also carried out on
brain and liver extracts from C57BL/WldS mutant mice, which
constitutively express the axon-protective protein chimera WldS,
endowed with NMNAT1 activity [40,41]. As a result, only the
activity accounted by isoform 1, a combination of mNMNAT1
and WldS contributions, was found to be 3–6 times higher than in
the corresponding wild type tissues (Fig. 5), while no statistical
difference for the two other isozymes was observed (Student’s t-test
p values $0.1). Furthermore, as expected, no statistical alteration
on NAD tissue content was observed in WldS mutant with respect
to wild-type (Student’s t-test p values $0.1).
Discussion
In this work, a novel method for simultaneous activity
discrimination of NMNAT isozymes in complex mixtures, like
mouse tissue extracts, has been developed to study the compart-
mentalized cellular NAD biosynthesis and its role in physiological
and pathological processes. The preliminary kinetic and catalytic
characterization of mNMNATs, carried out in vitro by using
recombinant isozymes, revealed properties broadly similar to their
human counterparts, consistent with the structural similarities, as
also recently reported by others for mNMNAT2 [42]. A known
exception in mouse is NMNAT1 which accepts the alternative
substrate ITP as well as low micromolar Mg2+ ions. WldS and
mNMNAT1 were catalytically and kinetically indistinguishable.
The discrimination assay method here described exploits the
distinctive metal ion dependence displayed by individual
mNMNATs, and introduces for the first time a matrix substitution
calculation to obtain simultaneously the unknown activity values of
Table 3. In vitro discrimination of mNMNAT activities (mU).
Experiment I Experiment II Experiment III Experiment IV
Ref. cond. A Error % Ref. cond. A Error % Ref. cond. A Error % Ref. cond. A Error %
mNMNAT1 1.33 25.1% 0.67 21.4% 1.60 +2.5% 1.43 +15%
mNMNAT2 0.54 +4.7% 1.27 28.1% 1.37 26.9% 2.40 25.1%
mNMNAT3 1.68 23.1% 1.99 +13% 2.04 23.0% 0.65 +2.8%
Summary of results from four discrimination experiments, each carried out independently according to the scheme in Table 2.
doi:10.1371/journal.pone.0053271.t003
Figure 4. Comparative activity and expression profiles of
individual mNMNATs in wild-type mouse brain. Tissues were
collected from 24 month old animals. Panel A) Activity of mNMNAT
isozymes from discrimination assay. Panel B) Real-time quantitative RT-
PCR analysis. Relative mRNA expression levels are normalized against b-
actin. Data are averages (+/2 SD) of triplicate experiments.
doi:10.1371/journal.pone.0053271.g004
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the three isozymes. After assessing the reliability of the method
using reconstituted mixtures of pure recombinant isozymes, the
procedure was tailored for assaying NMNAT isozymes in tissue
extracts from mouse. As this species is frequently used to model
human conditions, the ability to discriminate differential contribu-
tions to NAD synthesis in physio-pathological conditions is
particularly useful.
Main advantage of this method is that it allows quantitative
determination of the activity of the isozymes simultaneously
present in a given sample, without their prior physical separation.
Isozymes separation, such as one relying on their subcellular
compartmentation, e.g. by differential centrifugation, would be not
suitable for quantitative measurements essentially due to 1) cross-
contamination of fractionated particles, 2) not exclusive compart-
mentation of isozymes, which can be present in more than one
subcellular district [43,44], 3) incomplete recovery of a given
compartment due to particle rupture, 4) intrinsic isozyme in-
stability (e.g., NMNAT2 [36]). On the other hand, use of this
method can be instrumental to assess the level of different isozymes
simultaneously present in subcellular fractions obtained by
different fractionation methods, as well as to appraise the recovery
of individual isozymes following a fractionation step, and thus for
the quantitative comparison of different fractionation methods.
A fundamental requirement of this method is the preliminary
selection of appropriate assay conditions for discrimination,
encompassing biochemical, analytical, and mathematical features.
Biochemical features refer to the selection of assay mixtures
leading to consistently dissimilar isozyme reaction rate values.
Analytical requirements means that actual rate values should be
relatively high, in order to minimize the intrinsic experimental
error. The mathematical conditions dictate that the determinant of
the matrix employed is non-zero. Our selected conditions depicted
in Fig. 3 have been devised taking into account all these features,
leading to reliable and reproducible results within good confidence
limits, as reported in Tables 2 and 3. It can be noted that, for
matrix calculation, the internal normalization with respect to
recombinant isozyme rates minimizes experimental variance of
measured rate values, caused by factors such as freshness of
reagents. Thus, greater accuracy is achieved when activity ratio
coefficients for matrix calculation are determined on an individual-
experiment basis, or each time reagent stock solutions are
renewed. The convenience of this method is improved by the
observed stability of the recombinant mouse isozymes (Fig. 2).
Figure 5. Activity profiling of mNMNAT isozymes in brain and liver from wild-type mouse and WldS mutant. Tissues were collected
from 1 month old animals. The isozymes activities, measured by the described discrimination assay procedure, are color-coded as indicated (see
graph legend). Tissue contents of total NMNAT activity and NAD, respectively determined under reference assay condition ‘‘A’’ and by HPLC (see
Methods), are also shown. Each bar represents the average (+/2 SD) from at least a triplicate experiment.
doi:10.1371/journal.pone.0053271.g005
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Compared to the previously described discrimination assay
[13], this method has the advantage that it bypasses the need for
only one isozyme to be active in each selected assay condition. In
this view, it can be seen as an extension of the previous
methodology, whose enhanced statistical accuracy arises from
the matrix construction from multiple data points. It can be
further improved by selecting discrimination assay conditions
positively affecting the biochemical, analytical, or mathematical
features of the method. It is also amenable to future custom-
adaptation, e.g. by replacing HPLC with high-throughput NAD
quantitation based on microplate readers and fluorescence cycling
assays. Finally of course, it could be extended to mammalian
systems other than human and mouse, and to any other enzyme
existing in multiple isoforms (even four or more). The only
requirement is to establish a number of assay conditions that
differentially favour the various isoforms, yielding an appropriate
number of simultaneous equations for matrix calculation.
Efforts to elucidate the role played by the three mammalian
NMNAT isozymes in NAD biosynthesis have included a number
of expression and immunological studies on their tissue distribu-
tion and cellular localization [11,12,14,44]. However, as activity
levels may differ from both mRNA and protein levels, the
assessment of the individual contributions to compartmentalized
NAD biosynthesis was hampered by the inability to simultaneously
assay individual isozyme activities in crude cell extracts, thus
limiting the significance of the above data. This method is
intended to fill this gap. Our previous report first allowed a direct
determination of individual NMNAT activities in human brain
and liver tissue extracts [13]. In this work, the improved
discrimination assay yielded similar data using these same tissues
from mouse suggesting similar distribution patterns of isozyme
activity and validating mouse as a model for compartmentalized
NAD-biosynthesis in NAD-related human conditions and diseases
in these tissues. The main difference is the activity of NMNAT2,
which is comparable to NMNAT1 in mouse whole brain (Fig. 4A
and 5A), but predominant over other activities in the human brain
[13]. However, the human sample was a brain peritumoral
specimen, so it remains to be determined how closely this
represents the normal condition. Alternatively, it may reflect the
greater contribution of white matter, and hence NMNAT2-rich
axons, to human brain. Furthermore, the activity profile in mouse
brain does not contradict the relatively higher expression level of
NMNAT2 (Fig. 4B), given that its catalytic efficiency is way lower
than NMNAT1.
Furthermore, comparison of wild-type and WldS tissues by the
present discrimination assay revealed that the expected increase in
total NMNAT activity in WldS [40] was accounted for by only
isoform 1 activity, encompassing the indistinguishable contribu-
tions by both mNMNAT1 and WldS species. The activity of the
two other isozymes was unchanged in mutant tissues with respect
to wild-type, thus ruling out the occurrence of compensatory
changes in mNMNAT2 and mNMNAT3 expression. This is
consistent with independent, non-redundant functions of these
extra-nuclear NMNAT isozymes. Interestingly, in the opposite
case of ,50% NMNAT1 activity reduction, as observed in whole
brain from heterozygous NMNAT1 null mice, this method
showed that compensatory changes were similarly absent [2].
Indeed, the activities of mNMNAT1 and WldS are not discrim-
inated by our assay method, as we found no assay conditions
leading to consistently dissimilar reaction rates. Nonetheless, their
respective individual contribution could be determined by
comparing isoform 1 individual activity in wild-type and WldS
tissues. Alternatively, they could be likewise determined by
comparing overall NMNAT activity in wild-type and WldS tissues,
once unchanged mNMNAT2 and mNMNAT3 contributions have
been assessed by means of the discrimination assay. In both cases,
effective profiling of all three endogenous mNMNATs and WldS
enzyme activities could be achieved in WldS mutant tissues. As an
example, from data in Fig. 5, the WldS contribution to total NAD
synthesis can be estimated to account for ,0.4 mU/mg in brain,
and ,0.55 mU/mg in liver. Though partly indirect, this evidence
is only made possible by the application of the present
discrimination assay.
In conclusion, we have developed a novel method of wide
applicability to discriminate the individual activity of mammalian
NMNAT isozymes. Its preliminary application validated the study
of NAD biosynthesis in mouse tissues as a model for human
diseases. In particular, the method enables assessment in mouse
brain and liver of all known NMNAT reaction-catalysing
isozymes, including mNMNAT1, mNMNAT2, mNMNAT3,
and WldS. Additional preliminary experiments suggest this assay
can also be applied to mouse nerve tissue extracts (unpublished).
The ability to analyse individual isozyme fluctuations in a number
of physiological and pathological conditions will be important for
understanding the mechanism by which localized NMNAT
catalysis specifically contributes to axon viability, as well as in
other NAD-related conditions such as ageing and metabolic
disorders.
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